Composition, carbonylation inhibitor, and method for inhibiting carbonylation

Abstract

A composition capable of exhibiting an excellent carbonylation inhibitory effect is provided. The present invention relates to a composition comprising the following components (A) and (B): (A) Kelp rhizoid extract, (B) rosemary extract (B1) and / or phlorotannins (B2), A composition comprising:

Description

[Technical Field]

[0001] The present invention relates to a composition, a carbonylation inhibitor, and a method for inhibiting carbonylation. [Background technology]

[0002] In recent years, it has become clear that oxidative damage in the body caused by aging and environmental stress is the cause of various diseases and aging phenomena. In particular, it has been reported that protein carbonylation is induced by oxidative stress and is deeply involved in the decline of cellular function and tissue deterioration. Carbonylation occurs when oxidized lipids react with proteins. Such reactions cause structural changes and loss of function in proteins, and are thought to be involved in cosmetic problems such as dull skin, wrinkles, and sagging skin, as well as arteriosclerosis, diabetes, and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease (see, for example, Patent Document 1).

[0003] Previously, research aimed at inhibiting carbonylation has been conducted, and for example, Patent Document 2 discloses a carbonylation inhibitor containing Lithospermum Root extract. Patent Document 3 discloses a carbonylation inhibitor containing L-ascorbic acid glucoside as an active ingredient. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Laid-Open No. 2012-041276 [Patent Document 2] Japanese Patent Application Publication No. 2024-121685 [Patent Document 3] Japanese Patent Application Publication No. 2023-134261 Summary of the Invention [Problem to be solved by the invention]

[0005] As mentioned above, various components that inhibit carbonylation have been developed to date, but there is room for further investigation into components that exhibit a carbonylation inhibitory effect.

[0006] The present invention has been made in view of the above-mentioned current situation, and has as its object to provide a composition that can exert an excellent carbonylation inhibiting effect. [Means for solving the problem]

[0007] The inventors have conducted various studies on carbonylation inhibition and have found that a composition containing kelp rhizoid extract as component (A) and rosemary extract and / or phlorotannins as component (B) exhibits excellent carbonylation inhibition effects. They have come to the realization that this can successfully solve the above-mentioned problems and have arrived at the present invention.

[0008] The present invention includes the following compositions and the like. [1] The following components (A) and (B): (A) Kelp rhizoid extract, (B) rosemary extract (B1) and / or phlorotannins (B2), A composition comprising: [2] The composition according to [1] above, wherein the component (B) includes a rosemary extract (B1). [3] The composition according to [1] or [2] above, wherein the component (B) contains phlorotannins (B2). [4] The composition according to any one of [1] to [3] above, wherein the component (B) comprises a rosemary extract (B1) and phlorotannins (B2). [5] The composition according to any one of [2] to [4] above, further comprising a chestnut astringent skin extract (C). [6] The composition according to any one of [2] to [5] above, wherein the component (A) contains fucoidan (a), the component (B1) contains rosmarinic acid (b1), and the mass ratio of the rosmarinic acid (b1) to the fucoidan (a), ((b1) / (a)), is 0.001 to 1000. [7] The composition according to any one of [3] to [6] above, wherein the component (A) contains a fucoidan (a), and the mass ratio of the component (B2) to the fucoidan (a) ((B2) / (a)) is 0.01 to 1000. [8] The composition according to any one of [1] to [7] above, which is an oral composition. [9] The composition according to any one of [1] to [7] above, which is a food or drink, a pharmaceutical product, a quasi-drug, or a cosmetic.

[10] The following components (A) and (B): (A) Kelp rhizoid extract, (B) rosemary extract (B1) and / or phlorotannins (B2), A carbonylation inhibitor comprising:

[11] The following components (A) and (B): (A) Kelp rhizoid extract, (B) rosemary extract (B1) and / or phlorotannins (B2), A method for inhibiting carbonylation, comprising administering [Effects of the Invention]

[0009] The composition of the present invention has the above-mentioned constitution and can exhibit an excellent carbonylation inhibitory effect, and therefore can be suitably used in foods and drinks, pharmaceuticals, quasi-drugs, cosmetics, and the like. DETAILED DESCRIPTION OF THE INVENTION

[0010] Preferred embodiments of the present invention will be specifically described below, but the present invention is not limited to the following description and can be appropriately modified and applied within the scope of the present invention. Note that combinations of two or more of the individual preferred embodiments of the present invention described below also fall within the scope of preferred embodiments of the present invention.

[0011] [Composition] The composition of the present invention comprises the following components (A) and (B): (A) Kelp rhizoid extract, (B) rosemary extract (B1) and / or phlorotannins (B2), The combination of the above components (A) and (B) exhibits an excellent carbonylation inhibitory effect. The composition of the present invention may contain a kelp rhizoid extract (A) and a rosemary extract (B1), a kelp rhizoid extract (A) and phlorotannins (B2), or a kelp rhizoid extract (A), a rosemary extract (B1), and phlorotannins (B2). Of these, a composition containing a kelp rhizoid extract (A) and a rosemary extract (B1) is preferred, and a composition containing a kelp rhizoid extract (A), a rosemary extract (B1), and phlorotannins (B2) is more preferred.

[0012] As described below, the kelp rhizoid extract (A) contains fucoidans (a) such as L-fucoidan and Ga-fucoidan as active ingredients, and the rosemary extract (B1) contains rosmarinic acid (b1) as an active ingredient. When the composition of the present invention contains rosemary extract (B1), the mass ratio of rosmarinic acid (b1) to fucoidan (a) is not particularly limited, but is preferably 0.001 to 1000. This allows the effects of the present invention to be more effectively exhibited. The mass ratio ((b1) / (a)) is more preferably 0.005 to 800, even more preferably 0.01 to 700, and particularly preferably 0.02 to 650. In one embodiment, the mass ratio ((b1) / (a)) may be 0.1 to 500, 0.5 to 250, or 1 to 125. In one embodiment, the mass ratio ((b1) / (a)) may be 0.01 to 100, 0.05 to 80, or 0.1 to 70.

[0013] When the composition of the present invention contains phlorotannins (B2), the mass ratio of the phlorotannins (B2) to the fucoidan (a) ((B2) / (a)) is not particularly limited, but is preferably 0.01 to 1000, more preferably 0.05 to 800, even more preferably 0.1 to 700, and particularly preferably 0.15 to 650. In one embodiment, the mass ratio ((B2) / (a)) may be 1-500, 5-400, or 10-350. In one embodiment, the mass ratio ((B2) / (a)) may be 0.1-300, 0.5-200, or 1-100.

[0014] When the composition of the present invention contains rosemary extract (B1) and phlorotannins (B2), the mass ratio of the phlorotannins (B2) to rosmarinic acid (b1) ((B2) / (b1)) is not particularly limited, but is preferably 0.001 to 50, more preferably 0.03 to 20, and even more preferably 0.05 to 10. In one embodiment, the mass ratio ((B2) / (b1)) may be 0.1-50, 0.5-30, or 1-25. In one embodiment, the mass ratio ((B2) / (b1)) may be 0.1-30, 0.5-15, or 1-8.

[0015] When the composition of the present invention contains rosemary extract (B1), it is also preferable that it further contains chestnut astringent skin extract (C). As described below, chestnut astringent skin extract (C) contains proanthocyanidin (c) as an active ingredient. When the composition of the present invention contains rosemary extract (B1) and chestnut astringent skin extract (C), the mass ratio ((c) / (b1)) of the proanthocyanidin (c) to rosmarinic acid (b1) is not particularly limited, but is preferably 0.001 to 50, more preferably 0.05 to 20, even more preferably 0.1 to 10, and particularly preferably 0.1 to 2. In one embodiment, the mass ratio ((c) / (b1)) may be 0.01 to 10, 0.05 to 8, or 0.1 to 5.

[0016] In the composition of the present invention, the content of fucoidan, which is the active ingredient of component (A), is not particularly limited and can be set depending on the form, etc. In one embodiment, the content of the fucoidan is preferably 0.001 to 10% by mass, more preferably 0.01 to 5% by mass, even more preferably 0.05 to 1% by mass, and particularly preferably 0.1 to 0.5% by mass, relative to 100% by mass of the composition. The fucoidan content can be measured by high performance liquid chromatography (HPLC).

[0017] In the composition of the present invention, the content of rosmarinic acid (b1), which is the active ingredient of component (B1), is not particularly limited and can be set depending on the form, etc. In one embodiment, the content of the rosmarinic acid (b1) is preferably 0 to 15% by mass, more preferably 0.001 to 10% by mass, and even more preferably 0.05 to 7% by mass, relative to 100% by mass of the composition. In another embodiment, the content of the rosmarinic acid (b1) may be 0.1 to 3% by mass. The content of rosmarinic acid (b1) can be measured by high performance liquid chromatography (HPLC).

[0018] In the composition of the present invention, the content of the phlorotannins (B2) is not particularly limited and can be set depending on the form, etc. In one embodiment, the content of the phlorotannins (B2) is preferably 0 to 10% by mass, more preferably 0.001 to 5% by mass, even more preferably 0.01 to 3% by mass, and particularly preferably 0.05 to 1.5% by mass, relative to 100% by mass of the composition. The content of phlorotannins can be measured by the Folin-Ciocalteu method.

[0019] In the composition of the present invention, the content of proanthocyanidin, which is the active ingredient of component (C), is not particularly limited and can be set depending on the form and the like. In one embodiment, the content of the proanthocyanidins is preferably 0 to 10% by mass, more preferably 0.001 to 5% by mass, even more preferably 0.01 to 3% by mass, and particularly preferably 0.05 to 1% by mass, relative to 100% by mass of the composition. The proanthocyanidin content can be measured by the Folin-Ciocalteu method.

[0020] The essential and optional components contained in the composition of the present invention are further described below.

[0021] (Kelp rhizoid extract (A)) The kelp rhizoid extract (A) is obtained by extracting kelp rhizoids as a raw material with various solvents, and contains fucoidans such as L-fucoidan and Ga-fucoidan as active ingredients. The "kelp rhizoid" is a part that mainly consists of the rhizoid part of kelp and may also include the petiole. Ordinary kelp products are made from the parts of the thallus excluding the tip and bottom end, and the bottom end of the thallus is called root kelp and is used, but the above-mentioned adventitious root part is a part that was previously discarded and not used for food.

[0022] The fucoidan in the kelp rhizoid extract (A) contains L-fucoidan and Ga-fucoidan. Fucoidan is a general term for sulfated polysaccharides found in seaweed and other sources, with fucose as the main component, and its components and structure vary depending on the raw material. Fucoidan extracted from kelp rhizoids contains L-fucoidan and Ga-fucoidan in a ratio of 1:1 to 2:1. L-fucoidan is also found in the thallus and is composed of fucose and galactose, while Ga-fucoidan is unique to the rhizoids, has a high uronic acid content, and is primarily composed of fucose, with mannose, xylose, and glucose in addition to galactose. Ga-fucoidan is not found in other seaweeds or thallus. The kelp rhizoid extract (A) may contain a fucoidan other than L-fucoidan and Ga-fucoidan.

[0023] The extraction method for obtaining the kelp rhizoid extract (A) is not particularly limited, and examples thereof include hot water extraction, boiling extraction, immersion extraction, shaking extraction, Soxhlet extraction, steam distillation, etc. Boiling extraction is preferred.

[0024] Examples of solvents used in the extraction include water, lower alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, and 2-butanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerin, acetonitrile, esters such as ethyl acetate and butyl acetate, hydrocarbons such as hexane, heptane, liquid paraffin, and chloroform, and ethers such as ethyl ether, tetrahydrofuran, and propyl ether. One or more of these solvents can be used.

[0025] The kelp rhizoid extract (A) may be extracted from kelp rhizoids, or a commercially available product may be used.

[0026] (Rosemary extract (B1)) Rosemary (Rosmarinus officinalis) is an evergreen shrub native to the Mediterranean coastal region and belonging to the Lamiaceae family. As a raw material for rosemary extract, any of the whole rosemary plant, leaves, roots, stems, flowers, fruits, and seeds may be used, but it is preferable to use leaves. In general, it is preferable to chop the leaves before use to increase the extraction efficiency.

[0027] The rosemary extract (B1) contains rosmarinic acid (b1) (systematic name: (2''R'')-2-[[(2''E'')-3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-3-(3,4-dihydroxyphenyl)propanoic acid) as an active ingredient. The rosmarinic acid (b1) in the present invention includes free rosmarinic acid and derivatives of rosmarinic acid, such as rosmarinic acid glycosides in which a sugar such as glucose is glycosylated at one of the hydroxyl groups, but is not limited to these. When the composition of the present invention contains a derivative of rosmarinic acid, its mass is calculated in terms of free rosmarinic acid.

[0028] The rosemary extract (B1) can be obtained by a commonly used method using various solvents, similar to the kelp rhizoid extract (A), and commercially available products may also be used.

[0029] (Phlorotannins (B2)) Phlorotannin is a type of polyphenol derived from seaweed, and is a polymer having phloroglucinol as a basic skeleton unit. In the present invention, the phlorotannin may be a single compound or two or more compounds.

[0030] The phlorotannins (B2) used in the present invention may be commercially available, chemically synthesized, or extracted and isolated from various natural products, preferably phlorotannins extracted from seaweed. The extraction solvent and extraction method for obtaining the phlorotannins (B2) are not particularly limited, and commonly used solvents and methods such as those described for the kelp rhizoid extract (A) can be used.

[0031] Examples of seaweed containing phlorotannins (B2) include algae of the genus Ascophyllum, kelp, Sargassum, Eisenia bicolor, Eisenia elegans, Kurome, Tsuruarame, Wakame, and Mozuku, among others. Among these, Eisenia bicolor, Eisenia elegans, Kurome, and Tsuruarame are preferred.

[0032] (Chestnut skin extract (C)) The chestnut astringent skin extract (C) is obtained by extracting chestnut astringent skin as a raw material with various solvents, and contains proanthocyanidin (c) as an active ingredient. Proanthocyanidins are polymers whose constituent units are flavan-3-ol and / or flavan-3,4-diol. In the present invention, the proanthocyanidin (c) may be one type of compound or two or more types of compounds.

[0033] The chestnuts used as the raw material for the chestnut astringent skin extract (C) are not particularly limited, and any of Japanese chestnuts, Western chestnuts, Chinese chestnuts, and American chestnuts can be used. The raw material may be the astringent skin collected from raw chestnuts after peeling, or may be dried and crushed. Alternatively, the astringent skin may be collected from chestnuts that have been roasted, heated, frozen, dried, or boiled. For extraction, it is preferable to use finely crushed astringent skin.

[0034] The chestnut astringent skin extract (C) can be obtained by a commonly used method using various solvents, similar to the kelp rhizoid extract (A), and commercially available products may also be used.

[0035] [Uses of the composition] The composition of the present invention contains components (A) and (B) and has an excellent carbonylation inhibitory effect, and therefore can be suitably used for improving skin clarity, inhibiting skin dullness (more specifically, yellowish dullness), inhibiting wrinkle formation, inhibiting skin sagging, anti-aging, etc.

[0036] The compositions of the present invention can be used for either therapeutic (medical) or non-therapeutic (non-medical) purposes, the latter being a concept that does not include medical procedures, i.e., human surgery, treatment, or diagnosis. The composition of the present invention can be in the form of a food or drink, a pharmaceutical product, a quasi-drug, a cosmetic, a feed, etc. The composition of the present invention may be a material or a preparation to be incorporated into a food or drink, a pharmaceutical product, a quasi-drug, a cosmetic, a feed, etc.

[0037] In one embodiment, the composition of the present invention is preferably an oral composition. Specific examples of oral compositions include foods and beverages, oral medicines, quasi-drugs, feeds, etc., and are preferably foods and beverages or oral medicines, more preferably foods and beverages.

[0038] The composition of the present invention may contain optional additives and optional components in addition to components (A) and (B) and optional component (C), as long as the effects of the present invention are not impaired. These additives and components can be selected depending on the form of the composition, and those that can generally be used in foods and beverages, pharmaceuticals, quasi-drugs, cosmetics, feed, etc. can be used. When the composition of the present invention is used as a food and beverage, pharmaceutical, quasi-drug, cosmetic, feed, etc., the production method thereof is not particularly limited, and it can be produced by a general method. The form of the composition of the present invention is not particularly limited, and may be a solid (powder, granules, tablet, etc.), liquid, paste, or the like.

[0039] For example, when the composition of the present invention is made into a food or beverage, various foods and beverages can be made by blending components that can be used in foods and beverages (e.g., food ingredients, food additives used as needed, etc.) with components (A) and (B) (and component (C) as needed). The food and drink products are not particularly limited, and examples thereof include general food and drink products, health foods, health supplements, health drinks, functional food products, foods for specified health uses, foods for patients, etc. The health foods, health supplements, functional food products, foods for specified health uses, etc. can be used in various dosage forms such as fine granules, tablets, granules, powders, capsules, chewable tablets, dry syrups, syrups, liquids, beverages, drinks, and liquid diets.

[0040] When the composition of the present invention is used as a pharmaceutical or quasi-drug, for example, components (A) and (B) (and optionally component (C)) can be blended with pharmacologically acceptable carriers, additives added as needed, and the like to produce pharmaceuticals or quasi-drugs in various dosage forms. Such carriers, additives, and the like may be any pharmacologically acceptable carriers that can be used in pharmaceuticals or quasi-drugs, and examples thereof include one or more of excipients, binders, disintegrants, lubricants, antioxidants, colorants, and the like. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewable tablets, and the like.

[0041] When the composition of the present invention is used as a feed, components (A) and (B) (and optionally component (C)) can be blended into the feed. Feed also includes feed additives. Examples of feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; and pet food for dogs, cats, small birds, etc.

[0042] The subject to which the composition of the present invention is ingested or administered (also referred to as the administration subject) is not particularly limited, and is preferably a human or a non-human mammal, more preferably a human.

[0043] The composition of the present invention is preferably taken orally (administered orally). The dosage (which can also be referred to as intake amount) of the composition of the present invention is not particularly limited. The dosage of the composition of the present invention may be an amount that can obtain the carbonylation inhibitory effect, and may be appropriately determined depending on the dosage form, administration method, subject weight, etc.

[0044] The composition of the present invention may be used as an external preparation for the skin such as a skin cosmetic, a quasi-drug, or a pharmaceutical product. Specific examples include a beauty serum, an ointment, a cream, an emulsion, a lotion, a face mask, a foundation, a lip balm, a bath additive, a hair tonic, a hair lotion, a soap, and a body shampoo.

[0045] [Carbonylation inhibitors] The present invention relates to a composition comprising the following components (A) and (B): (A) Kelp rhizoid extract, (B) rosemary extract (B1) and / or phlorotannins (B2), It is also a carbonylation inhibitor containing

[0046] The carbonylation inhibitor is not particularly limited as long as it contains components (A) and (B). Specific examples, preferred forms, and blending ratios of components (A) and (B) are as described above for the composition of the present invention. The carbonylation inhibitor may also contain optional components such as component (C), and specific examples, preferred forms and blending ratios thereof are as described above for the composition of the present invention.

[0047] [Method for inhibiting carbonylation] The present invention relates to a composition comprising the following components (A) and (B): (A) Kelp rhizoid extract, (B) rosemary extract (B1) and / or phlorotannins (B2), It is also a method for inhibiting carbonylation by administering

[0048] In the above method, components (A) and (B) may be used in amounts sufficient to obtain a carbonylation inhibiting effect (which may also be referred to as an effective amount). Components (A) and (B) may be ingested or administered as they are, or may be ingested or administered as a composition containing them. For example, the composition of the present invention may be ingested or administered. The dosage of the composition of the present invention may be any amount that provides a carbonylation inhibitory effect, and may be appropriately determined depending on the dosage form, administration method, subject weight, etc. [Example]

[0049] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples. Unless otherwise specified, "%" means "% by mass."

[0050] <Carbonylation inhibition evaluation test> A 10 mg / mL aqueous solution of acrolein (Fujifilm Wako Pure Chemical Industries, Ltd., hereafter referred to as Acr) and human serum albumin (Fujifilm Wako Pure Chemical Industries, Ltd., hereafter referred to as HSA) were prepared at concentrations of 0.1 mol / L and 20 mg / mL, respectively, using 0.1 mol / L phosphate buffer (pH 7.4) (Fujifilm Wako Pure Chemical Industries, Ltd., hereafter referred to as PB). Next, the 50 mM standard reagent in the Carbonyl Assay Kit (BioAssay Systems) was prepared at a concentration of 250 μM using distilled water. The prepared solutions are mixed in the wells of a 96-well UVPlate, no lid with UV transparent flat bottom (manufactured by Corning Japan, hereinafter referred to as the plate) in the following ratios to prepare reaction solutions.

[0051] (Sample measurement solution) 0.1 mol / L Acr: sample solution: 20 mg / mL HSA = 1:5:4 (Sample blank measurement solution) 0.1 mol / L Acr: sample solution: 20 mg / mL HSA = 1:5:4 (Blank measurement solution) 0.1mol / L Acr:PB:20mg / mL HSA=1:5:4 A microplate seal (manufactured by Azbio Corporation, hereinafter referred to as seal) is attached to the plate to prevent drying, and the plate is incubated in a thermo-hygrostat (37°C, 60% RH) for 120 minutes. After 120 minutes, remove the plate from the thermo-hygrostat. Mix the prepared 250 μM standard with distilled water as follows to prepare a calibration curve measurement solution. (Calibration curve measurement solution) 250μM Standard 100μL and distilled water 0μL 60 μL of 250 μM Standard and 40 μL of distilled water 30 μL of 250 μM Standard and 70 μL of distilled water 0 μL of 250 μM Standard and 100 μL of distilled water *

[0052] Next, add 100 μL of the reagent in the Carbonyl Assay Kit to the wells containing the sample measurement solution, blank measurement solution, and calibration curve measurement solution, and add 100 μL of PB to the wells containing the sample blank measurement solution. The plate is gently tapped to mix the liquid, and then incubated in a thermo-humidistat (25°C, 60% RH) for 30 minutes. After 30 minutes, the plate is removed from the thermo-hygrostat and the absorbance at a wavelength of 375 nm is immediately measured using a microplate reader Infinite 200 PRO M Plex (manufactured by Tecan Japan Co., Ltd.). The slope of the calibration curve is calculated from the absorbance values ​​of 250, 150, 75, and 0 μM standards added to the wells as calibration curve measurement solutions.

[0053] Furthermore, the concentration of the carbonyl compound in the solution [Carbonyl] (μM) is calculated from the absorbance value obtained as follows:

[0054]

number

[0055]

number

[0056] <Examples 1 to 11, Comparative Examples 1 and 2> Components (A), (B1), (B2), and (C) were mixed according to the blending ratios shown in Table 1 to prepare compositions. The resulting composition was subjected to a carbonylation inhibition evaluation test, and the results are shown in Table 1. Details of the components used in preparing the compositions are as follows: Ingredient (A): Cultivated kelp rhizoid extract powder (Kaigen Pharma Co., Ltd., fucoidan content 3-6%) Ingredient (B1): Rosemary dried extract (manufactured by ASK Pharmaceutical Co., Ltd., essential oil content 2.0 mL / 100 g or more, rosmarinic acid content 2.5% or more) Ingredient (B2): Seaweed extract powder (manufactured by Kaigen Pharma Co., Ltd., phlorotannins 20% or more) Ingredient (C): Japanese chestnut astringent skin extract (manufactured by Bio-i Co., Ltd., total polyphenol content 20% or more)

[0057] [Table 1]

Claims

1. Components (A) and (B) below: (A) kelp rhizoid extract, (B) rosemary extract (B1) and / or phlorotannins (B2), A composition comprising:

2. The composition of claim 1 , wherein component (B) comprises rosemary extract (B1).

3. The composition of claim 1 , wherein the component (B) comprises phlorotannins (B2).

4. The composition according to claim 1, wherein the component (B) comprises rosemary extract (B1) and phlorotannins (B2).

5. The composition according to claim 2 or 4, further comprising a chestnut astringent skin extract (C).

6. 3. The composition according to claim 2, wherein the component (A) contains a fucoidan (a), the component (B1) contains a rosmarinic acid (b1), and the mass ratio of the rosmarinic acid (b1) to the fucoidan (a), ((b1) / (a)), is 0.001 to 1000.

7. 4. The composition according to claim 3, wherein the component (A) contains a fucoidan (a), and the mass ratio of the component (B2) to the fucoidan (a), ((B2) / (a)), is 0.01 to 1000.

8. The composition of claim 1, which is an oral composition.

9. The composition according to claim 1, which is a food or drink, a pharmaceutical product, a quasi-drug, or a cosmetic.

10. Components (A) and (B) below: (A) kelp rhizoid extract, (B) rosemary extract (B1) and / or phlorotannins (B2), A carbonylation inhibitor comprising:

11. Components (A) and (B) below: (A) kelp rhizoid extract, (B) rosemary extract (B1) and / or phlorotannins (B2), A method for inhibiting carbonylation (excluding methods for treating humans) comprising administering

Images